REDWOOD CITY, Calif., June 22, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that data from the SENZA Non-Surgical Refractory Back Pain (NSRBP) Randomized Controlled Trial (RCT) will be presented at the American Society of Interventional Pain Physicians (ASIPP) 23rd annual meeting to be held in person from June 24-26, 2021 at the Hilton New Orleans Riverside in New Orleans, Louisiana. Nevro will also showcase the company's HFX™ platform of spinal cord stimulation (SCS) solutions in an exhibit booth and will host an investor briefing.
The podium presentation will describe the 6-month follow-up results from the SENZA-NSRBP RCT. The objective of this study was to compare Nevro's proprietary high-frequency (10 kHz) SCS plus Conventional Medical Management (CMM) to CMM alone in 159 randomized patients at 15 study centers. Previously presented 3-month results demonstrated superior responder rate and significant pain relief for the 10 kHz SCS cohort versus CMM.
"This will be the first time that 6-month data from our SENZA-NSRBP clinical trial will be presented, and we look forward to Dr. Kapural sharing these significant results at the ASIPP annual meeting," stated D. Keith Grossman, Chairman, CEO and President of Nevro. "NSRBP represents an important growth driver for Nevro, and these results will provide valuable evidence to guide clinical decisions and to support our initiatives to expand payer coverage as we continue to increase penetration into the non-surgical portion of our market."
Six Month Outcomes from Randomized Clinical Trial for Efficacy of Spinal Cord Stimulation at 10 kHz to treat Non-Surgical Refractory Back Pain Presenting Author: Leonardo Kapural, MD, PhD Date & Time: Friday, June 25, 2021 during Breakout Sessions - Abstract Session A from 3:30 pm to 5:30 pm Central Time
The company plans to publish these 6-month results in a peer-reviewed journal. Study participants will continue to be followed out to 24 months.
Nevro to Host Analyst & Investor Briefing on June 25, 2021
Nevro will host an analyst & investor briefing on Friday, June 25, beginning at 3:30 pm PT / 6:30 pm ET. Nevro Chairman, CEO and President D. Keith Grossman will host the event, which will include a clinical data update for the company's SENZA-PDN and SENZA-NSRBP clinical studies and a question & answer session. Nevro's Chief Medical Officer, David Caraway, MD, PhD, and Nevro's Chief Financial Officer, Rod MacLeod, will also participate in the event.
About the American Society of Interventional Pain Physicians
ASIPP is a not-for-profit professional organization founded in 1998 now comprising over 4,500 interventional pain physicians and other practitioners who are dedicated to ensuring safe, appropriate and equal access to essential pain management services for patients across the country suffering with chronic and acute pain. There are approximately 8,500 appropriately trained and qualified physicians practicing interventional pain management in the United States. ASIPP is comprised of 50 affiliated state societies, and the Puerto Rico Society of Interventional Pain Physicians. For more information, please visit the ASIPP website at asipp.org.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. Nevro's proprietary 10 kHz Therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.
In addition to historical information, this press release contains forward-looking statements reflecting the company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: the Company's belief that NSRBP represents an important growth driver and that the SENZA-NSRBP results will provide valuable evidence to guide clinical decisions and to support the Company's initiatives to expand payer coverage as it continues to increase penetration into the non-surgical portion of the SCS market. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth and the costs and expenses of operating our business; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Quarterly Report on Form 10-Q filed on May 5, 2021, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.